
Opinion|Videos|October 21, 2026
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
Author(s)Michael S. Cookson, MD, MMHC, FACS
Fact checked by: Hannah Clarke
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Advertisement
Advertisement
In this video, Michael S. Cookson, MD, MMHC, FACS, discusses the significance of the FDA’s expanded approval of nogapendekin alfa inbakicept-pmln (Anktiva) plus BCG for patients with BCG-unresponsive high-risk non–muscle-invasive
Related to this article

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.

Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.

Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.

BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.

Patient priorities and practice logistics should guide therapy selection in BCG-unresponsive NMIBC, according to Katie S. Murray, DO, MS, FACS.
Advertisement
Advertisement

